| Literature DB >> 24642747 |
Na Li1, Runmei Liu1, Hongxia Zhai1, Liang Li1, Yaxin Yin1, Jinjin Zhang1, Yunfeng Xia1.
Abstract
OBJECTIVE: The lymphotoxin-α (LTA), as one of the mediators of inflammation, may play an important role in the pathogenesis of myocardial infarction (MI). Genetic association studies (GAS) that have investigated the association between three common polymorphisms (A252G, G10A and C804A) of the LTA gene and susceptibility to MI have produced contradictory and inconclusive results. The aim of this meta-analysis is to provide a relatively comprehensive account of the association of these polymorphisms with susceptibility to MI.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24642747 PMCID: PMC3958506 DOI: 10.1371/journal.pone.0092272
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1The potential roles of SNPs in the LTA gene in inflammatory process and the pathogenesis of myocardial infarction.
Figure 2Flow diagram of the selection of studies and specific reasons for exclusion from the present meta-analysis.
Main characteristics and methodological quality of all eligible studies.
| First author, year | Country | Ethnicity | No. of cases, age(y) | No. of controls, age(y) | Male (%) [Case/Control] | Genotyping method | Variant(s) | STREGA score | NOS star |
| Padovani JC, 2000 | Brazil | Caucasian | 148, mean 43 range (25–55) | 148, mean 42 range (22–55) | 82.5%, 82.5% | PCR-RFLP | A252G | 19/22 | 8/9 |
| Koch W, 2001 | Germany | Caucasian | 793, mean 62.6 (SD 10.2) | 340, mean 63.4 (SD 10.3) | 77.4%, 75.3% | AS-PCR | A252G | 17/22 | 7/9 |
| Iwanaga Y, 2004 | Japan | Asian | 477, mean 56 (SD 8) | 372, mean 59 (SD 9) | 100%, 100% | TaqMan | A252G, G10A, C804A | 18/22 | 7/9 |
| Tobin MD, 2004 | UK | Caucasian | 547, mean 61.9 (SD 9.2) | 505, mean 58.6 (SD 10.7) | 68%, 62% | PCR-RFLP | C804A | 16/22 | 6/9 |
| Yamada A, 2004 | Japan | Asian | 1891, mean 60.6 (SD 10.9) | 1798, mean 58.6 (SD 11.3) | 78.9%, 55.2% | AS-PCR | A252G, C804A | 17/22 | 7/9 |
| Ozaki K, 2005 | Japan | Asian | 1133, mean 62.5 (SD 11.3) | 1006, mean 64.3 (SD 11.3) | NA, NA | PCR-RFLP | A252G, G10A, C804A | 20/22 | 8/9 |
| Clarke R, 2006 | UK | Caucasian | 6928, mean 54.8 (SD 7.3) | 2712, mean 46.2 (SD 9.6) | 82.3%, 44.6% | TaqMan | A252G, G10A, C804A | 19/22 | 8/9 |
| Tanaka T, 2006 | Japan | Asian | 2833, NA | 3399, NA | NA, NA | PCR-RFLP | C804A | 15/22 | 6/9 |
| Kimura A, 2007 | Japan | Asian | 533, mean 59.4 (SD 10.1) | 683, mean 43.3 (SD 10.9) | 83.3%, 67.7% | PCR-RFLP | A252G | 17/22 | 7/9 |
| Kimura A, 2007 | Korea | Asian | 448, mean 61.3 (SD 11.9) | 160, mean 61.3 (SD 8.8) | 82.4%, 83.5% | PCR-RFLP | A252G | 17/22 | 7/9 |
| Koch W, 2007 | Germany | Caucasian | 3657, mean 64.0 (SD 12.0) | 1211, mean 60.3 (SD 11.9) | 75.8%, 50.0% | TaqMan | A252G, G10A, C804A | 19/22 | 8/9 |
| Sedlacek K, 2007 | Germany | Caucasian | 1821, mean 58.7 (SD 8.6) | 2572, mean 57.4 (SD 9.7) | 78.0%, 43.2% | TaqMan | G10A, C804A | 18/22 | 7/9 |
| Panoulas VF, 2008 | UK | Caucasian | 388, mean 61.5 (SD 12.0) | 399, mean 50.2 (SD 15.8) | 26.8%, 39.6% | PCR-MCA | A252G | 16/22 | 6/9 |
| Ryan AW, 2008 | Irish | Caucasian | 835, mean 61.9 (SD 8.5) | 691, mean 52.4 (SD 10.0) | NA, NA | PCR-RFLP | A252G | 15/22 | 6/9 |
| Wang YC, 2010 | Taiwan | Asian | 117, NA | 109, NA | NA, NA | AS-PCR | A252G, C804A | 14/22 | 5/9 |
NA, Not available; SD, Standard deviate; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, Allele specific-polymerase chain reaction; PCR-MCA, Polymerase chain reaction-melting curve analysis; STREGA, Strengthening the reporting of genetic association studies; NOS, Newcastle-Ottawa scale.
Meta-analysis of the association between LTA A252G and the risk of myocardial infarction (MI).
| Subgroups | No. of study | G allele vs. A allele | AG+GG vs. AA | GG vs. AA+AG | GG vs. AA | GG vs. AG | ||||||||||
| (Case/Control) | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | |
| Overall | 12 (17,348/9,629) | 1.08 | 0.99–1.18 | 0.082 | 1.08 | 0.93–1.26 | 0.306 | 1.20 | 1.01–1.44 | 0.040 | 1.21 | 1.01–1.45 | 0.039 | 1.23 | 0.98–1.55 | 0.069 |
| Ethnicity | ||||||||||||||||
| Caucasian | 6 (12,749/5,501) | 1.00 | 0.88–1.13 | 0.970 | 0.93 | 0.75–1.16 | 0.534 | 1.16 | 0.88–1.54 | 0.303 | 1.07 | 0.83–1.39 | 0.607 | 1.30 | 0.87–1.94 | 0.201 |
| Asian | 6 (4,599/4,128) | 1.16 | 1.07–1.26 | <0.001 | 1.26 | 1.04–1.54 | 0.020 | 1.28 | 1.04–1.56 | 0.018 | 1.35 | 1.16–1.58 | <0.001 | 1.21 | 0.94–1.55 | 0.142 |
| Source of control | ||||||||||||||||
| PB | 11 (15,457/7,831) | 1.09 | 0.98–1.20 | 0.113 | 1.09 | 0.91–1.29 | 0.358 | 1.22 | 0.99–1.51 | 0.056 | 1.23 | 0.99–1.51 | 0.058 | 1.26 | 0.97–1.64 | 0.088 |
| HB | 1 (1,891/1,798) | 1.08 | 0.98–1.19 | 0.103 | 1.13 | 0.98–1.29 | 0.083 | 1.08 | 0.91–1.28 | 0.409 | 1.15 | 0.95–1.39 | 0.155 | 1.03 | 0.86–1.23 | 0.789 |
| HWE status | ||||||||||||||||
| HWE | 11 (16,215/8,623) | 1.08 | 0.98–1.18 | 0.141 | 1.10 | 0.92–1.30 | 0.295 | 1.15 | 0.97–1.36 | 0.105 | 1.16 | 0.97–1.40 | 0.100 | 1.18 | 0.94–1.49 | 0.149 |
| Non-HWE | 1 (1,133/1,006) | 1.16 | 1.03–1.31 | 0.019 | 1.02 | 0.85–1.22 | 0.838 | 1.69 | 1.32–2.15 | <0.001 | 1.58 | 1.21–2.06 | 0.001 | 1.77 | 1.37–2.29 | <0.001 |
| Genotyping method | ||||||||||||||||
| PCR-RFLP | 5 (3,097/2,688) | 1.06 | 0.90–1.25 | 0.506 | 0.93 | 0.66–1.32 | 0.699 | 1.52 | 1.30–1.77 | <0.001 | 1.33 | 1.09–1.62 | 0.005 | 1.69 | 1.16–2.44 | 0.006 |
| Non-PCR-RFLP | 7 (14,251/6,941) | 1.10 | 0.98–1.23 | 0.105 | 1.18 | 1.00–1.40 | 0.049 | 1.05 | 0.87–1.27 | 0.639 | 1.14 | 0.90–1.45 | 0.289 | 0.99 | 0.85–1.16 | 0.915 |
OR, Odd ratio; 95%CI, 95% confidence interval; HB, Hospital-based; PB, Population-based; HWE, Hardy-Weinberg equilibrium; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism.
Figure 3Forest plots of ORs for the association between the LTA A252G polymorphism and susceptibility to myocardial infarction in subgroup analysis based on ethnicity under the recessive model (A) and the homozygous model (B).
Meta-analysis of the association between LTA G10A and myocardial infarction risk.
| Genetic model | Subgroup | No. of study (CA/CO) | OR [95% CI] | POR | Ph | Method |
| A allele vs. G allele | Overall | 5 (14,653/7,873) | 1.05 [0.95, 1.17] | 0.349 | <0.001 | RE |
| (Allele model) | Asian | 2 (1,610/1,378) | 1.25 [1.09, 1.45] | 0.002 | 0.203 | FE |
| Caucasian | 3 (12,406/6,495) | 0.97 [0.92, 1.02] | 0.179 | 0.449 | FE | |
| HWE | 4 (12,883/6,867) | 1.02 [0.92, 1.13] | 0.749 | 0.004 | RE | |
| Non-HWE | 1 (1,133/1,006) | 1.19 [1.05, 1.34] | 0.007 | - | FE | |
| GA + AA vs. GG | Overall | 5 (14,653/7,873) | 1.01 [0.96, 1.07] | 0.651 | 0.014 | RE |
| (Dominant model) | Asian | 2 (1,610/1,378) | 1.17 [1.01, 1.36] | 0.034 | 0.010 | RE |
| Caucasian | 3 (12,406/6,495) | 0.99 [0.93, 1.05] | 0.682 | 0.520 | FE | |
| HWE | 4 (12,883/6,867) | 1.01 [0.95, 1.08] | 0.737 | 0.006 | RE | |
| Non-HWE | 1 (1,133/1,006) | 1.04 [0.87, 1.24] | 0.682 | - | FE | |
| AA vs. GG + GA | Overall | 5 (14,653/7,873) | 1.07 [0.82, 1.41] | 0.618 | <0.001 | RE |
| (Recessive model) | Asian | 2 (1,610/1,378) | 1.63 [1.27, 2.08] | <0.001 | 0.255 | FE |
| Caucasian | 3 (12,406/6,495) | 0.88 [0.78, 1.00] | 0.051 | 0.222 | FE | |
| HWE | 4 (12,883/6,867) | 0.92 [0.78, 1.09] | 0.350 | 0.062 | RE | |
| Non-HWE | 1 (1,133/1,006) | 1.78 [1.39, 2.27] | <0.001 | - | FE | |
| AA vs. GG | Overall | 5 (14,653/7,873) | 1.10 [0.84, 1.44] | 0.498 | <0.001 | RE |
| (Homozygous model) | Asian | 2 (1,610/1,378) | 1.69 [1.35, 2.11] | <0.001 | 0.874 | FE |
| Caucasian | 3 (12,406/6,495) | 0.89 [0.78, 1.00] | 0.059 | 0.271 | FE | |
| HWE | 4 (12,883/6,867) | 0.97 [0.78, 1.22] | 0.799 | 0.008 | RE | |
| Non-HWE | 1 (1,133/1,006) | 1.67 [1.28, 2.18] | <0.001 | - | FE | |
| AA vs. GA | Overall | 5 (14,653/7,873) | 1.00 [0.91, 1.10] | 0.975 | <0.001 | RE |
| (Heterozygous model) | Asian | 2 (1,610/1,378) | 1.61 [1.30, 2.00] | <0.001 | 0.035 | RE |
| Caucasian | 3 (12,406/6,495) | 0.89 [0.80, 0.99] | 0.030 | 0.219 | FE | |
| HWE | 4 (12,883/6,867) | 0.90 [0.79, 1.02] | 0.087 | 0.252 | FE | |
| Non-HWE | 1 (1,133/1,006) | 1.87 [1.44, 2.41] | <0.001 | - | FE |
CA, Case group; CO, Control group; OR, Odd ratio; 95%CI, 95% confidence interval; P, P value of heterogeneity; HWE, Hardy-Weinberg equilibrium; RE, Random-effect model; FE, Fix-effect model.
Figure 4Forest plots of ORs for the association between the LTA G10A polymorphism and susceptibility to myocardial infarction in subgroup analysis based on ethnicity under the allele model (A) and the homozygous model (B).
Meta-analysis of the association between LTA C804A and the risk of myocardial infarction (MI).
| Subgroups | No. of study | A allele vs. C allele | CA+AA vs. CC | AA vs. CC+CA | AA vs. CC | AA vs. CA | ||||||||||
| (Case/Control) | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | OR | 95%CI | P | |
| Overall | 9 (19,404/13,684) | 1.11 | 1.04–1.17 | 0.001 | 1.10 | 1.01–1.19 | 0.020 | 1.24 | 1.08–1.41 | 0.002 | 1.21 | 1.01–1.45 | <0.001 | 1.21 | 1.04–1.39 | 0.012 |
| Ethnicity | ||||||||||||||||
| Caucasian | 4 (12,953/7,000) | 1.03 | 0.98–1.08 | 0.234 | 1.02 | 0.95–1.08 | 0.628 | 1.11 | 0.98–1.26 | 0.097 | 1.27 | 1.11–1.45 | 0.099 | 1.11 | 0.98–1.26 | 0.113 |
| Asian | 5 (6,451/6,684) | 1.17 | 1.09–1.25 | <0.001 | 1.20 | 1.05 –1.37 | 0.007 | 1.35 | 1.10–1.66 | 0.004 | 1.41 | 1.20–1.66 | <0.001 | 1.28 | 1.00–1.65 | 0.052 |
| Source of control | ||||||||||||||||
| PB | 8 (17,513/11,886) | 1.11 | 1.04–1.19 | 0.003 | 1.10 | 1.00–1.20 | 0.043 | 1.27 | 1.09–1.48 | 0.002 | 1.29 | 1.11–1.51 | 0.001 | 1.24 | 1.06–1.46 | 0.009 |
| HB | 1 (1,891/1,798) | 1.08 | 0.98–1.18 | 0.113 | 1.13 | 0.98–1.29 | 0.083 | 1.07 | 0.90–1.27 | 0.459 | 1.14 | 0.94–1.38 | 0.174 | 1.02 | 0.85–1.22 | 0.857 |
| HWE status | ||||||||||||||||
| HWE | 8 (18,271/12,678) | 1.10 | 1.03–1.17 | 0.005 | 1.11 | 1.02–1.21 | 0.021 | 1.18 | 1.05–1.32 | 0.006 | 1.22 | 1.07–1.39 | 0.002 | 1.14 | 1.02–1.28 | 0.024 |
| Non-HWE | 1 (1,133/1,006) | 1.19 | 1.05–1.34 | 0.007 | 1.04 | 0.87–1.24 | 0.689 | 1.78 | 1.39–2.27 | <0.001 | 1.67 | 1.28–2.18 | <0.001 | 1.87 | 1.44–2.41 | <0.001 |
| Genotyping method | ||||||||||||||||
| PCR-RFLP | 3 (4,513/4,910) | 1.16 | 1.10–1.23 | <0.001 | 1.11 | 1.02–1.20 | 0.018 | 1.45 | 1.17–1.79 | 0.001 | 1.46 | 1.26–1.69 | <0.001 | 1.44 | 1.11–1.86 | 0.006 |
| TaqMan | 4 (12,883/6,867) | 1.07 | 0.98–1.18 | 0.132 | 1.08 | 0.95–1.23 | 0.255 | 1.14 | 0.99–1.30 | 0.072 | 1.18 | 0.99–1.42 | 0.069 | 1.11 | 0.97–1.26 | 0.120 |
| AS-PCR | 2 (2,008/1,907) | 1.16 | 0.92–1.47 | 0.215 | 1.36 | 0.85–2.16 | 0.196 | 1.07 | 0.90–1.26 | 0.455 | 1.15 | 0.95–1.39 | 0.151 | 1.01 | 0.85–1.21 | 0.891 |
OR, Odd ratio; 95%CI, 95% confidence interval; HB, Hospital-based; PB, Population-based; HWE, Hardy-Weinberg equilibrium; PCR-RFLP, Polymerase chain reaction-restriction fragment length polymorphism.
Figure 5Forest plots of ORs for the association between the LTA C804A polymorphism and susceptibility to myocardial infarction in subgroup analysis based on ethnicity under the allele model (A) and the dominant model (B).
Figure 6Begg's funnel plots of publication bias for the associations the LTA A252G (A), G10A (B) and C804A (C) polymorphisms and susceptibility to myocardial infarction under the allele model.